BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 375526)

  • 41. Ovarian follicular and luteal physiology.
    Channing CP; Schaerf FW; Anderson LD; Tsafriri A
    Int Rev Physiol; 1980; 22():117-201. PubMed ID: 6248477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The induction of ovulation in amenorrheic patients with synthetic luteinizing hormone-releasing hormone: the significance of pituitary responsiveness.
    Huang KE
    Fertil Steril; 1976 Jan; 27(1):65-71. PubMed ID: 1107074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulsatile luteinizing hormone secretion in hypothalamic amenorrhea, anorexia nervosa, and polycystic ovarian disease during naltrexone treatment.
    Armeanu MC; Berkhout GM; Schoemaker J
    Fertil Steril; 1992 Apr; 57(4):762-70. PubMed ID: 1555686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
    Fraser HM; Lunn SF; Morris KD; Deghenghi R
    Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
    Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
    Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue.
    Bergquist C; Nillius SJ; Bergh T; Skarin G; Wide L
    Acta Endocrinol (Copenh); 1979 Aug; 91(4):601-8. PubMed ID: 386680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days.
    Baird DT; Thong KJ; Hall C; Cameron ST
    Hum Reprod; 1995 Sep; 10(9):2270-6. PubMed ID: 8530650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delay of the selective surge of follicle-stimulating hormone by bovine follicular fluid during the period of ovulation induced by human chorionic gonadotrophin in dioestrous rats.
    Sasamoto S; Otani T; Shirota M
    J Endocrinol; 1981 May; 89(2):205-12. PubMed ID: 6787162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pituitary responsiveness to luteinizing hormone-releasing hormone during treatment with subdermal D-norgestrel implants in women.
    Weiner E; Nillius SJ; Wide L; Johansson ED
    Acta Obstet Gynecol Scand Suppl; 1979; 88():23-6. PubMed ID: 393048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gonadotrophic control of follicular development and function during the oestrous cycle of the ewe.
    Baird DT; McNeilly AS
    J Reprod Fertil Suppl; 1981; 30():119-33. PubMed ID: 6300383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovulation and normal luteal function during LHRH treatment of women with hyperprolactinaemic amenorrhoea.
    Polson DW; Sagle M; Mason HD; Adams J; Jacobs HS; Franks S
    Clin Endocrinol (Oxf); 1986 May; 24(5):531-7. PubMed ID: 3539412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of follicular development and ovulation in seasonally acyclic mares using gonadotrophin-releasing hormones and progesterone.
    Evans MJ; Irvine CH
    J Reprod Fertil Suppl; 1979; (27):113-21. PubMed ID: 383982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternate-day GnRH therapy for ovarian hypofunction induced by weight loss: treatment of six patients who remained amenorrhoeic after weight gain.
    Kotsuji F; Kubo M; Takeuchi Y; Tominaga T
    Clin Endocrinol (Oxf); 1993 Dec; 39(6):641-8. PubMed ID: 8287581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.